Advances in Urologic Imaging Prostate-Specific Membrane Antigen Ligand PET Imaging

被引：31

作者：

Hofman, Michael S. ^{[1
,2
]}

Iravani, Amir ^{[1
]}

Nzenza, Tatenda ^{[3
,4
]}

Murphy, Declan G. ^{[3
]}

机构：

[1] Peter MacCallum Canc Ctr, Ctr Mol Imaging, Dept Canc Imaging, 305 Grattan St, Melbourne, Vic 3000, Australia

[2] Univ Melbourne, Sir Peter MacCallum Dept Oncol, 305 Grattan St, Melbourne, Vic 3000, Australia

[3] Univ Melbourne, Sir Peter MacCallum Dept Surg Oncol, 305 Grattan St, Melbourne, Vic 3000, Australia

[4] Austin Hosp, 305 Grattan St, Melbourne, Vic 3000, Australia

来源：

UROLOGIC CLINICS OF NORTH AMERICA | 2018年 / 45卷 / 03期

关键词：

Prostate cancer; Prostate-specific membrane antigen; PET; PSMA PET/CT; PSMA PET; EMISSION TOMOGRAPHY/COMPUTERIZED TOMOGRAPHY; SMALL-MOLECULE INHIBITORS; MONOCLONAL-ANTIBODY J591; ESTRO-SIOG GUIDELINES; LYMPH-NODE DISSECTION; PART II TREATMENT; RADIATION-DOSIMETRY; MAGNETIC-RESONANCE; GA-68-PSMA PET/CT; BIOCHEMICAL RECURRENCE;

D O I：

10.1016/j.ucl.2018.03.016

中图分类号：

R5 [内科学]; R69 [泌尿科学（泌尿生殖系疾病）];

学科分类号：

1002 ; 100201 ;

摘要：

Radiolabeled prostate-specific membrane antigen (PSMA) PET is emerging as an important modality for imaging prostate cancer (PCa). Promising clinical experience has led to increasing number of studies exploring the role of PSMA PET in different aspects of PCa, including primary detection, risk stratification, targeted biopsy, initial staging, restaging at biochemical recurrence, biologic characterization, treatment response assessment, and prognostication. PSMA PET may prove an important disease biomarker, expand our understanding of the pathogenesis, and pave the way for personalized management of PCa.

引用

页码：503 / +

页数：23

共 128 条

[1] Impact of 68Ga-Prostate-Specific Membrane Antigen PET/CT on Prostate Cancer Management [J].

Afaq, Asim ;

Alahmed, Suliman ;

Chen, Shih-hsin ;

Lengana, Thabo ;

Haroon, Athar ;

Payne, Heather ;

Ahmed, Hashim ;

Punwani, Shonit ;

Sathekge, Mike ;

Bomanji, Jamshed .

JOURNAL OF NUCLEAR MEDICINE, 2018, 59 (01) :89-92

[2] PET imaging with a [68Ga]gallium-labelled PSMA ligand for the diagnosis of prostate cancer: biodistribution in humans and first evaluation of tumour lesions [J].

Afshar-Oromieh, A. ;

Malcher, A. ;

Eder, M. ;

Eisenhut, M. ;

Linhart, H. G. ;

Hadaschik, B. A. ;

Holland-Letz, T. ;

Giesel, F. L. ;

Kratochwil, C. ;

Haufe, S. ;

Haberkorn, U. ;

Zechmann, C. M. .

EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING, 2013, 40 (04) :486-495

[3] Radiation dosimetry of 68Ga-PSMA-11 (HBED-CC) and preliminary evaluation of optimal imaging timing [J].

Afshar-Oromieh, Ali ;

Hetzheim, Henrik ;

Kuebler, Wolfgang ;

Kratochwil, Clemens ;

Giesel, Frederik L. ;

Hope, Thomas A. ;

Eder, Matthias ;

Eisenhut, Michael ;

Kopka, Klaus ;

Haberkorn, Uwe .

EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING, 2016, 43 (09) :1611-1620

[4] PET/MRI with a 68Ga-PSMA ligand for the detection of prostate cancer [J].

Afshar-Oromieh, Ali ;

Haberkorn, Uwe ;

Hadaschik, Boris ;

Habl, Gregor ;

Eder, Matthias ;

Eisenhut, Michael ;

Schlemmer, Heinz-Peter ;

Roethke, Matthias C. .

EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING, 2013, 40 (10) :1629-1630

[5] Diagnostic accuracy of multi-parametric MRI and TRUS biopsy in prostate cancer (PROMIS): a paired validating confirmatory study [J].

Ahmed, Hashim U. ;

Bosaily, Ahmed El-Shater ;

Brown, Louise C. ;

Gabe, Rhian ;

Kaplan, Richard ;

Parmar, Mahesh K. ;

Collaco-Moraes, Yolanda ;

Ward, Katie ;

Hindley, Richard G. ;

Freeman, Alex ;

Kirkham, Alex P. ;

Oldroyd, Robert ;

Parker, Chris ;

Emberton, Mark .

LANCET, 2017, 389 (10071) :815-822

[6] Clinical impact of 68Ga-prostate-specific membrane antigen (PSMA) positron emission tomography/computed tomography (PET/CT) in patients with prostate cancer with rising prostate-specific antigen after treatment with curative intent: preliminary analysis of a multidisciplinary approach [J].

Albisinni, Simone ;

Artigas, Carlos ;

Aoun, Fouad ;

Biaou, Ibrahim ;

Grosman, Julien ;

Gil, Thierry ;

Hawaux, Eric ;

Limani, Ksenija ;

Otte, Francois-Xavier ;

Peltier, Alexandre ;

Sideris, Spyridon ;

Sirtaine, Nicolas ;

Flamen, Patrick ;

van Velthoven, Roland .

BJU INTERNATIONAL, 2017, 120 (02) :197-203

[7] Expression of the Gastrin-Releasing Peptide Receptor, the Prostate Stem Cell Antigen and the Prostate-Specific Membrane Antigen in Lymph Node and Bone Metastases of Prostate Cancer [J].

Ananias, Hildo J. K. ;

van den Heuvel, Marius C. ;

Helfrich, Wijnand ;

de Jong, Igle J. .

PROSTATE, 2009, 69 (10) :1101-1108

[8] Multisite Experience of the Safety, Detection Rate and Diagnostic Performance of Fluciclovine (18F) Positron Emission Tomography/Computerized Tomography Imaging in the Staging of Biochemically Recurrent Prostate Cancer [J].

Bach-Gansmo, Tore ;

Nanni, Cristina ;

Nieh, Peter T. ;

Zanoni, Lucia ;

Bogsrud, Tronde Velde ;

Sletten, Heidi ;

Korsan, Katrine Andersen ;

Kieboom, J. ;

Tade, Funmilayo I. ;

Odewole, Oluwaseun ;

Chau, Albert ;

Ward, Penelope ;

Goodman, Mark M. ;

Fanti, Stefano ;

Schuster, David M. ;

Willoch, Frode .

JOURNAL OF UROLOGY, 2017, 197 (03) :676-682

[9] A Randomized Controlled Trial To Assess and Compare the Outcomes of Two-core Prostate Biopsy Guided by Fused Magnetic Resonance and Transrectal Ultrasound Images and Traditional 12-core Systematic Biopsy [J].

Baco, Eduard ;

Rud, Erik ;

Eri, Lars Magne ;

Moen, Gunnar ;

Vlatkovic, Ljiljana ;

Svindland, Aud ;

Eggesbo, Heidi B. ;

Ukimura, Osamu .

EUROPEAN UROLOGY, 2016, 69 (01) :149-156

[10] Targeting metastatic prostate cancer with radiolabeled monoclonal antibody J591 to the extracellular domain of prostate specific membrane antigen [J].

Bander, NH ;

Trabulsi, EJ ;

Kostakoglu, L ;

Yao, D ;

Vallabhajosula, S ;

Smith-Jones, P ;

Joyce, MA ;

Milowsky, M ;

Nanus, DM ;

Goldsmith, SJ .

JOURNAL OF UROLOGY, 2003, 170 (05) :1717-1721

← 1 2 3 4 5 6 7 8 9 10 →